Waverley Pharma Announces $3,000,000 Credit Facility
Waverley Pharma Announces Successful Tender Award for Capecitabine with NHS Scotland
Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States
Waverley Pharma Announces Listing on the Frankfurt Stock Exchange (FSE: 5GZ)
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy
Waverley Pharma Announces Grant of Market Authorization of Pemetrexed and Bortezomib in Multiple European Countries
Waverley Pharma Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19
Waverley Pharma Announces Appointment of New President and CEO
Waverley Pharma Announces Executive Leadership Changes
Waverley Pharma Announces Grant of Marketing Authorization in the United Kingdom for Erlotinib
Waverley Pharma Provides Market Update and Fiscal 2018 Preliminary Revenue
Waverley Pharma Announces Distribution Agreement and First Sale of Generic Oncology Products in the United Kingdom
Waverley Pharma Announces Resignation of CEO and Appointment of New CEO
Waverley Pharma Announces Filing of Two Abbreviated New Drug Applications in the United States
Waverley Pharma Announces Acquisition of two Generic Oncology Products Currently Marketed in the United Kingdom
Waverley Pharma Announces Filing of its Second Marketing Authorization Application in Select European Union Countries
